secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K/A
Filed at:   2026-08-06T19:45:05+00:00
Accession:  0001493152-26-036326
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce acquires Cy Biopharma and up to $77M private financing for CRPS drug
----------------------------------------------------------------------------

- Acquisition of Cy Biopharma includes clinical-stage neuroplastogenic therapy CY200 for CRPS with FDA Orphan Drug Designation.
- Up to $77M financing: $21.5M initial private placement, $17.1M from Cy Biopharma cash, plus $38.6M milestone tranche.
- Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept and into registrational development.
- James Morrison, Cy Biopharma CEO, becomes President of Ensysce and joins Board of Directors.
- Post-acquisition ownership: Cy Biopharma holders ~74.94%, Ensysce ~7.57%, new investors ~17.49%; combined equity value ~$122.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226036326/0001493152-26-036326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226036326/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer